Selected article for: "good safety profile and safety profile"

Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA
  • Document date: 2018_6_28
  • ID: tudwns0r_82
    Snippet: The efficacies of the 10-del ZIKA and 20-del ZIKA vaccines were compared in a study using rhesus macaques. There were four groups, a positive control with wt ZIKV administered on day 0 (n ¼ 4), active groups vaccinated (10 3 IFU sc) with 10-del ZIKA (n ¼ 4) and 20-del ZIKA (n ¼ 3) vaccines, respectively, and a placebo control (n ¼ 2). Viraemia was measured from day 2 to 10 and antibody levels from day 2 to 56. On day 56, all groups were chall.....
    Document: The efficacies of the 10-del ZIKA and 20-del ZIKA vaccines were compared in a study using rhesus macaques. There were four groups, a positive control with wt ZIKV administered on day 0 (n ¼ 4), active groups vaccinated (10 3 IFU sc) with 10-del ZIKA (n ¼ 4) and 20-del ZIKA (n ¼ 3) vaccines, respectively, and a placebo control (n ¼ 2). Viraemia was measured from day 2 to 10 and antibody levels from day 2 to 56. On day 56, all groups were challenged with ZIKV (PRVABC59, 10 3 PFU). Viraemia was measured from day 58 to 66 and antibody levels from day 70 to 98. As expected, the infected control group had high viraemia, high antibody levels from day 14 and had no viraemia after virus challenge. The placebo group had neither viraemia nor antibodies until after the virus challenge. Following vaccination with 10-del ZIKA vaccine, only 1/4 animals had detectable viraemia, 4/4 had moderate levels of antibodies which rose more than four-fold on virus challenge. In spite of the suboptimal levels of antibodies, no viraemia was detected after the virus challenge. In the 20-del ZIKA vaccine group, 2/3 had low levels of viraemia and 3/3 with high antibody levels from day 14 onwards. After virus challenge, there was minimal increase in antibody levels (0/ 4 with a four-fold rise) and there was no viraemia. Both deletion vaccines appeared to have a good safety profile.

    Search related documents:
    Co phrase search for related documents
    • active group and fold rise: 1
    • active group and good safety profile: 1
    • antibody level and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • antibody level and high antibody level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody level and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody moderate level and high antibody level: 1, 2
    • antibody moderate level and low level: 1
    • antibody viraemia and detectable viraemia: 1, 2
    • antibody viraemia and high viraemia: 1, 2
    • control group and day measure: 1, 2, 3, 4, 5, 6, 7
    • control group and detectable viraemia: 1
    • control group and fold rise: 1, 2
    • control group and good safety profile: 1, 2, 3, 4
    • control group and high viraemia: 1
    • control group and infected control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control group and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • deletion vaccine and fold rise: 1
    • deletion vaccine and low level: 1
    • detectable viraemia and high viraemia: 1